Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth

Cancer Research

Volumn 60, Issue 6, 2000, Pages 1492-1497

  Bateman, Andrew ^a   Bullough, Francis ^b   Murphy, Stephen ^a   Emiliusen, Lisa ^a   Lavillette, Dimitri ^c   Cosset, François Loic ^c   Cattaneo, Roberto ^a   Russell, Stephen J ^a   Vile, Richard G ^a  

^a MAYO CLINIC   (United States)

^b Cambridge Systems Associates Limited   (United Kingdom)

^c CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER; CANCER IMMUNOLOGY; CONTROLLED STUDY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CELL DIVISION; CELL FUSION; CELL LINE; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PLASMIDS; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSFECTION; TUMOR CELLS, CULTURED; VIRAL FUSION PROTEINS;

EID: 0034653696     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Moolten, F. L. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther., 1: 279-287, 1994.
2. Peng, K-W., and Vile, R. Vector development for cancer gene therapy. Tumor Targeting, 4: 3-11, 1999.
3. Colombo, M. P., Modesti, A., Parmiani, G., and Forni, G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res., 52: 4853-4857, 1992.
4. Pardoll, D. M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol., 13: 399-415, 1995.
5. Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow derived cells in presenting MHC Class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
6. Cayeux, S., Richter, G., Becker, C., Pezzutto, A., Dorken, B., and Blankenstein, T. Direct and indirect T cell priming by dendritic cell vaccines. Eur. J. Immunol., 29: 255-234, 1999.
7. Vile, R. G., Castleden, S. C., Marshall, J., Camplejohn, R., Upton, C., and Chong, H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk-killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer, 71: 267-274, 1997.
8. Melcher, A. A., Todryk, S., Hardwick, N., Ford, M., Jacobson, M., and Vile, R. G. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat. Med., 4: 581-587, 1998.
9. Todryk, S., Melcher, A. A., Hardwick, N., Linardakis, E., Bateman, A., Colombo, M. P., Stoppacciaro, A., and Vile, R. G. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J. Immunol., 163: 1398-1408, 1999.
10. Klasse, P. J., Bron, R., and Marsh, M. Mechanisms of enveloped virus entry into animal cells. Adv. Drug Delivery Rev., 34: 65-91, 1998.
11. Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., and Yee, J. K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA. 90: 8033-8037, 1993.
12. Cathomen, T., Naim, H. Y., and Cattaneo, R. Measles virus with altered envelope protein cytoplasmic tails gain cell fusion competence. J. Virol., 72: 1224-1234, 1998.
13. Ghosh, S., Paweletz, N., and Schroeter, D. Cdc2-independent induction of premature mitosis by okadaic acid in HeLa cells. Exp. Cell Res., 242: 1-9, 1998.
14. Vile, R. G., and Hart, I. R. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res., 53: 3860-3864, 1993.
15. Vile, R. G., Nelson, J. A., Castleden, S., Chong, H., and Hart, I. R. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res., 54: 6228-6234, 1994.
16. Diaz, R. M., Eisen, T., Hart, I. R., and Vile, R. G. Exchange of viral promoter/ enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J. Virol., 72: 789-795, 1998.
17. Bentley, N. J., Eisen, T., and Goding, C. Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol. Cell. Biol., 14: 7996-8006, 1994.
18. Matzinger, P. An innate sense of danger. Semin, Immunol., 10: 399-415, 1998.
19. Tamura, Y., Peng, P., Liu, K., Daou, M., and Srivastava, P. K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (Washington DC), 278: 117-120, 1997.
20. Chong, H., Todryk, S., Hutchinson, G., Hart, I. R., and Vile, R. G. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Ther., 5: 223-232, 1998.